Results 181 to 190 of about 73,667 (245)

Characterisation of RT Connection and RNase H Polymorphisms in HIV-1 Subtype C in Botswana. [PDF]

Viruses
Zuze BJL, Choga WT, Moraka-Mankge NO, Choga OT, Bhebhe L, Maruapula D, Phuthego T, Mokomane M, Moyo S, Gaseitsiwe S.   +9 more
europepmc   +1 more source

Enhanced strand transfer and mismatch extension by HIV-1C reverse transcriptase promote sequence motif duplication. [PDF]

J Virol
Panchapakesan A, Joshi AP, Amanullah A, Pargain N, Mehta K, Shanmugam M, Singh J, Saini C, Nala N, Ramagopal UA, Ranga U.   +10 more
europepmc   +1 more source

Integrating haplotype-enhanced HIV surveillance with national databases improves the resolution of transmission networks, drug resistance, and risk assessment. [PDF]

Emerg Microbes Infect
Cai D, Feng Y, Gan M, Li H, Wang D, Hao J, Lin L, Tang Y, Wang Y, Liao L, Wang Z, Xing H.   +11 more
europepmc   +1 more source

HIV-1 Genetic Diversity and Drug Resistance Mutations Among Patients on Antiretroviral Therapy in Nairobi County, Kenya. [PDF]

Adv Virol
Angiro E, Ngayo M, Wahome C, Mungiria J, Nyamache A.   +4 more
europepmc   +1 more source

Synthesis, in vitro anti-HIV-1 reverse transcriptase evaluation, molecular modelling, DFT analysis and acute oral toxicity assessment of benzotriazole derivatives. [PDF]

Sci Rep
Maiti NJ, Ganguly S, Choowongkomon K, Seetaha S, Saehlee S, Aiebchun T, Ghosh R, Khan MA, Debnath B, Nath R, Ashique S, Singh NK, Ansari MY, Tariq M, Niazi P.   +14 more
europepmc   +1 more source

Regional Variations of Rates and Determinants of Drug Resistance Mutations in People Failing First-line Therapy for HIV-1: A Substudy from the D2EFT Phase 3b/4 Clinical Trial. [PDF]

Clin Infect Dis
Obeng BM, Hutchinson J, Shaik A, Chetchotisakd P, Azwa I, Wulan WN, Kumarasamy N, Wolff M, Bruguera J, Losso M, Kaplan R, Diallo MS, Eriobu N, Musoro G, Kumalawati J, Badamasi A, Fitriah M, Mulya DP, Law M, Matthews G, Di Giallonardo F, Kelleher AD, Dolutegravir and Darunavir Evaluation in Adults Failing Therapy (D2EFT) Study Group.   +22 more
europepmc   +1 more source

Antiretroviral resistance in at least second-line HIV-1 treatment virologic failure with common InSTI-based regimens. [PDF]

AIDS
Marcelin AG, Soulie C, Wirden M, Gruber J, Prata Menezes N, Lim T, Barriere G, Descamps D, Charpentier C, Calvez V.   +9 more
europepmc   +1 more source

Factors associated with low-level viremia in people living with HIV: A 10-year retrospective study in South Korea. [PDF]

PLoS One
Yang E, Kim S, Kim DH, Ahn MY, Choi JP.
europepmc   +1 more source

Antiretroviral Activity, Pharmacokinetics, and Safety of MK-8527, an Oral Nucleoside Reverse Transcriptase Translocation Inhibitor, in Adults With HIV-1 Who Had Not Previously Taken Antiretroviral Agents: Results From 2 Open-Label, Phase 1 Studies. [PDF]

Clin Infect Dis
Carstens RP, Kapoor Y, Vargo RC, Bhattacharyya A, Garrett G, Cilissen C, Adedoyin A, Zang X, Denef JF, Leyssens C, Reynders T, Preotescu L, Kaplan R, Rassool M, Lombaard J, Streinu-Cercel A, Matthews RP, Stoch SA, Iwamoto M, Gillespie GL.   +19 more
europepmc   +1 more source

Allophycocyanin inhibits HIV-1 gp120 and reverse transcriptase through enthalpy-driven binding and antioxidative protection: integrative computational and experimental insights. [PDF]

Sci Rep
Dubey A, Kumar M, Tufail A, Anand K, Sengupta S.   +4 more
europepmc   +1 more source